Looking at EV+P as first treatment for advanced urothelial cancer
Part of Cancer, Kidney & urinary clinical trials.
This study looks back at medical records of people with advanced or metastatic urothelial cancer (a type of bladder or urinary tract cancer) who received the combination treatment EV+P as their first therapy. The goal is to understand how well this treatment works in real-world patients, which may help guide future treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have a tissue-confirmed diagnosis of urothelial cancer (a type of bladder or urinary tract cancer) or another rare urinary tract tumor.
- Your cancer must have spread to other parts of the body (metastatic) or be locally advanced (late stage).
- You must have received the combination of enfortumab vedotin and pembrolizumab (known as EV+P) as your first treatment for this cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (N-803, pembrolizumab, and enfortumab vedotin) for advanced bladder cancer that has not been treated with systemic therapy. The goal is to see if this combination can shrink or control the cancer and improve outcomes.
This trial tests a new drug, PF-08634404, either by itself or together with another drug called enfortumab vedotin, for people with advanced bladder cancer that has spread. The goal is to see if these treatments can shrink tumors or slow the cancer's growth.
This is a study that looks back at past medical records of adults with metastatic urinary tract cancer. It specifically includes people who received certain immunotherapy or antibody-drug treatments during set time periods, to help researchers understand outcomes and care patterns.
This trial tests a combination of two drugs (enfortumab vedotin and pembrolizumab) given before surgery to shrink or eliminate bladder or upper tract cancer. The goal is to see if this approach reduces the chance of cancer coming back and improves outcomes.
This study looks at the different ways doctors choose the first treatment for patients whose urothelial cancer has spread. It aims to understand what factors influence that choice, which could help improve care for future patients.
This trial tests a combination of two chemotherapy drugs, gemcitabine and carboplatin, for people whose bladder cancer has progressed after treatment with enfortumab vedotin plus pembrolizumab. The goal is to see if this chemo regimen can help control the cancer.
Hear when a new Urothelial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.